Rob Coffin

Biography

 Robert Coffin is CEO and co-founder of Replimune. Previously he was Founder & CTO of BioVex Inc, a spin out from his prior research group at University College London in 1999. Rob was the inventor of all BioVex products including OncoVEXGM-CSF (talimogene laherparepvec; T-VEC) that was recently approved by the FDA and is the first gene therapy product ever approved in the USA. Rob oversaw all research and clinical development including bringing T-VEC through to two pivotal phase 3 studies in melanoma and head & neck cancer under SPA before sale of BioVex to Amgen in 2011 where he became VP Global Development until 2013. Rob was awarded a PhD in virology from Imperial College London prior to his move to University College London in 1991. Subsequent to Amgen, Rob has provided general biotech advisory services in gene therapy, oncolytic viruses, oncology drug development, cell therapy, immunotherapy and vaccines including in particular to Uniqure and Universal Cells Inc.

Research Interest

 Oncology